Briacell Therapeutics Corp (BCTX)
4.95 x 1 4.98 x 1
Post-market by (Cboe BZX)
5.00 -0.20 (-3.85%) 04/28/25 [NASDAQ]
4.95 x 1 4.98 x 1
Post-market 4.95 -0.05 (-1.00%) 19:59 ET
for Mon, Apr 28th, 2025
Fiscal Year End Date: 07/31
(Values in U.S. thousands)
07-2024 | 07-2023 | 07-2022 | 07-2021 | 07-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -4,932 | -20,302 | -26,839 | -13,816 | -4,025 |
Depreciation Amortization | 84 | 15 | 15 | 15 | 15 |
Accounts receivable | -733 | 5 | -12 | 10 | -23 |
Accounts payable and accrued liabilities | 6,047 | 661 | 249 | -1,406 | N/A |
Other Working Capital | 7,053 | -3,532 | -391 | -2,282 | 2,666 |
Other Operating Activity | -31,646 | -592 | 14,493 | 9,729 | 100 |
Operating Cash Flow | $-24,126 | $-23,745 | $-12,484 | $-7,750 | $-1,266 |
Cash Flows From Investing Activities | |||||
PPE Investments | -457 | N/A | N/A | N/A | N/A |
Purchase Of Investment | -225 | N/A | N/A | N/A | N/A |
Investing Cash Flow | $-682 | $N/A | $N/A | $N/A | $N/A |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 411 |
Debt Issued | N/A | N/A | N/A | 216 | -389 |
Debt Repayment | N/A | N/A | N/A | -307 | N/A |
Common Stock Issued | 4,419 | 4,002 | 6,510 | 65,328 | 1,152 |
Common Stock Repurchased | N/A | -47 | -10,172 | N/A | N/A |
Other Financing Activity | 0 | 0 | -81 | -239 | 0 |
Financing Cash Flow | $4,419 | $3,954 | $-3,743 | $64,998 | $1,174 |
Exchange Rate Effect | N/A | N/A | N/A | N/A | -44 |
Beginning Cash Position | 21,251 | 41,042 | 57,269 | 21 | 157 |
End Cash Position | 862 | 21,251 | 41,042 | 57,269 | 21 |
Net Cash Flow | $-20,389 | $-19,791 | $-16,227 | $57,247 | $-136 |
Free Cash Flow | |||||
Operating Cash Flow | -24,126 | -23,745 | -12,484 | -7,750 | -1,266 |
Capital Expenditure | -457 | N/A | N/A | N/A | N/A |
Free Cash Flow | -24,583 | -23,745 | -12,484 | -7,750 | -1,266 |